Skip to main content
SpringerLink
Log in

Chemotherapy in Head and Neck Squamous Cell Cancer

  • Chapter
  • First Online:
Targeting Oral Cancer

Abstract

This chapter will outline the application of chemotherapy in head and neck squamous cell carcinoma (HNSCC) chronicling the evolution of treatment since its inception at the hands of Paul Ehrlich in the late 1800s. We will discuss the discoveries in cancer kinetics and the clinical trials that have established the current standards of treatment and conclude with a discussion of ongoing research endeavors. Surgical excision has remained the mainstay of curative efforts over the years. Contrary to many other cancers, HNSCC treatment failure tends to occur with locoregional recurrence. The addition of radiation therapy to advanced stage tumors and/or those with high-risk features has improved outcomes; adding chemotherapy in select cases has further improved our ability to treat HNSCC patients. By targeting rapidly dividing cancer cells, and more recently targeting-specific molecular signaling pathways of cancer cells, chemotherapy has become an important part in treatment of advanced stage HNSCC and remains the key player in palliative therapy of metastatic disease. Generally employed as adjuvant treatment together with radiation to improve locoregional control and prevent recurrence, concurrent chemoradiation therapy can also serve as organ preservation therapy in an attempt to avoid surgical removal of vital structures. Despite many clinical trials evaluating variations in chemotherapy modalities and agents, the standard of care has remained largely unchanged over the last 15 years. The emergence of HPV+ tumors has garnered much attention in the media, and while these tumors appear to behave differently and add further research questions, the publicity has sparked a tremendously needed increase in conversation about HNSCC and the gap in our ability to treat it. Recent research advances have positioned us on the horizon of a new field of chemotherapy that includes biotherapies such as the already utilized antibody cetuximab and T cell receptor ligands such as PD-L1, which is currently the subject of clinical trials for HNSCC and other late-stage solid tumors. Hope remains that as our understanding of the molecular biology of cancer evolves, an increasing array of agents including those targeting-specific molecular signaling pathways unique to cancer cells will become available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schwartz RS. Paul Ehrlich’s magic bullets. N Engl J Med. 2004;350(11):1079–80.

    Article  PubMed  Google Scholar 

  2. Kaufmann SH. Paul Ehrlich: founder of chemotherapy. Nat Rev Drug Discov. 2008;7(5):373.

    Article  PubMed  Google Scholar 

  3. DeVita Jr VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–53.

    Article  PubMed  Google Scholar 

  4. Chabner BA, Roberts Jr TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72.

    Article  PubMed  Google Scholar 

  5. Furth J, Kahn MC. The transmission of leukemia of mice with a single cell. Am J Cancer. 1937;31:276–82.

    Google Scholar 

  6. Skipper HE, Schabel FM Jr, Trader MW, Laster WR Jr, Simpson-Herren L, Lloyd HH. Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971. Cancer Chemother Rep Part 1. 1972;56(3):273–87, 89–314.

    Google Scholar 

  7. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. on the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep Part 1. 1964;35:1–111.

    Google Scholar 

  8. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11–12):1727–33.

    PubMed  Google Scholar 

  9. AJCC. American joint committee on cancer – cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  10. David GP, Kie-Kian A, David MB, Barbara AB, Paul MB, Jimmy JC, et al. NCCN Guidelines® Insights, Head and Neck Cancers. JNCCN. 2013;11:917–923

    Google Scholar 

  11. Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Biol Phys. 1992;23(4):737–42.

    Article  PubMed  Google Scholar 

  12. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52.

    Article  PubMed  Google Scholar 

  13. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44.

    Article  PubMed  Google Scholar 

  14. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685–90.

    Google Scholar 

  15. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949–55.

    Article  PubMed  Google Scholar 

  16. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.

    Article  PubMed  Google Scholar 

  17. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–52.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  PubMed  Google Scholar 

  19. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

    Article  PubMed  Google Scholar 

  20. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28(28):4390–9.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Andrade Filho PA, López-Albaitero A, Gooding W, Ferris RL. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother (Hagerstown, Md: 1997). 2010;33(1):83–91.

    Google Scholar 

  22. Gautam Gopalji Jha JSM. Potentiation of cetuximab by inhibition of tregs in metastatic squamous cell cancers of head and neck. J Clin Oncol. 31, 2013 (suppl; abstr TPS6101).

    Google Scholar 

  23. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338(25):1798–804.

    Article  PubMed  Google Scholar 

  24. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(5):1161–71.

    Article  PubMed  Google Scholar 

  25. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8.

    Article  PubMed  Google Scholar 

  26. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–9.

    Article  PubMed  Google Scholar 

  27. Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257–64.

    Article  PubMed  Google Scholar 

  28. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12(2):153–9.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–15.

    Article  PubMed  Google Scholar 

  30. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15(8):1179–86.

    Article  PubMed  Google Scholar 

  31. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43.

    Article  PubMed  Google Scholar 

  32. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704.

    Article  PubMed  Google Scholar 

  33. Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol. 2012;48(11):1076–84.

    Article  PubMed  Google Scholar 

  34. Zhong LP, Zhang CP, Ren GX, Guo W, William Jr WN, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31(6):744–51.

    Article  PubMed  Google Scholar 

  35. Adelstein DJ, Li Y, Adams GL, Wagner Jr H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–8.

    Article  PubMed  Google Scholar 

  36. Forastiere AA, Adelstein DJ, Manola J. Induction chemotherapy meta-analysis in head and neck cancer: right answer, wrong question. J Clin Oncol. 2013;31(23):2844–6.

    Article  PubMed  Google Scholar 

  37. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia-Giron C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25(1):216–25.

    Article  PubMed  Google Scholar 

  38. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350–6.

    PubMed  Google Scholar 

  39. Fury MG, Pfister DG. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Cancer Netw. 2011;9(6):681–9.

    Google Scholar 

  40. Grau JJ, Caballero M, Verger E, Monzo M, Blanch JL. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol. 2009;129(11):1294–9.

    Article  PubMed  Google Scholar 

  41. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–61.

    Google Scholar 

  42. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665–7.

    Article  PubMed  Google Scholar 

  43. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3–10.

    PubMed  Google Scholar 

  44. Kafri Z, Heilbrun LK, Sukari A, Yoo G, Jacobs J, Lin HS, et al. Phase II study of gemcitabine and docetaxel combination in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck. ISRN Oncol. 2012;2012:159568.

    PubMed Central  PubMed  Google Scholar 

  45. Sukari A, Al-Hajeili M, Salem M, Alousi A, Heilbrun LK, Smith D, et al. Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck. Avicenna J Med. 2015;5(2):36–41.

    Google Scholar 

  46. Deschler DG, Richmon JD, Khariwala SS, Ferris RL, Wang MB. The “new” head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg. 2014;151(3):375–80.

    Article  PubMed  Google Scholar 

  47. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703.

    Article  PubMed  Google Scholar 

  48. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(7):627–32.

    Article  PubMed  Google Scholar 

  49. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47(12):1148–53.

    Article  PubMed  Google Scholar 

  50. Zhang F, Liu Z, Cui Y, Wang G, Cao P. The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma. Lin chuang er bi yan hou tou jing wai ke za zhi = J Clin Otorhinolaryngol Head Neck Surg. 2008;22(9):408–10.

    Google Scholar 

  51. Ukpo OC, Thorstad WL, Lewis Jr JS. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2013;7(2):113–21.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology, Head and Neck Surgery, Wayne State University School of Medicine, 4201 St Antoine St 5E-UHC, Detroit, MI, 48201, USA

    Daniela M. Burchhardt BA, MD

  2. Fribley-Callaghan Collaboratory, Wayne State University School of Medicine, Detroit, MI, USA

    Daniela M. Burchhardt BA, MD

  3. Karmanos Cancer Institute, Detroit, MI, USA

    Daniela M. Burchhardt BA, MD

  4. Department of Oncology, Head and Neck Surgery, Wayne State University School of Medicine, 4100 John R, Detroit, MI, 48201, USA

    Ammar Sukari MD

  5. Karmanos Cancer Institute, Detroit, MI, 48201, USA

    Ammar Sukari MD

Authors
  1. Daniela M. Burchhardt BA, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ammar Sukari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Daniela M. Burchhardt BA, MD or Ammar Sukari MD .

Editor information

Editors and Affiliations

  1. School of Medicine, Wayne State University, DETROIT, Michigan, USA

    Andrew M. Fribley

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Burchhardt, D.M., Sukari, A. (2016). Chemotherapy in Head and Neck Squamous Cell Cancer. In: M. Fribley, A. (eds) Targeting Oral Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27647-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27647-2_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27645-8

  • Online ISBN: 978-3-319-27647-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation